Press release
Investigation announced for Investors who hold shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) over potential Wrongdoing
An investigation on behalf of current long term investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) shares.
Investors who are current long term investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in NASDAQ: ZBIO stocks follows a lawsuit filed against Zenas BioPharma, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ZBIO stocks, concerns whether certain Zenas BioPharma, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to the complaint the plaintiff alleges on behalf of purchasers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Registration Statement that was filed in connection with Zenas BioPharma's September 2024 IPO contained false and/or misleading statements and/or failed to disclose that Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO, and that as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.
Those who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who hold shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) over potential Wrongdoing here
News-ID: 4144709 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Primo Brands Corporati …
An investor, who purchased shares of Primo Brands Corporation (NYSE: PRMB), filed a lawsuit over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Primo Water (formerly NYSE: PRMW) between June 17, 2024 through November 8, 2024, and/or purchased a significant amount of shares Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 through November 6,…
Lawsuit Alert: Investors who lost a substantial amount with Telix Pharmaceutical …
An investor, who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Telix Pharmaceuticals Limited in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and for certain investors are short and strict deadlines running. Deadline: January 9, 2026. NASDAQ: TLX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in shares of Savara Inc. (NASDAQ …
An investigation was announced for long-term investors in shares of Savara Inc. (NASDAQ: SVRA) concerning potential breaches of fiduciary duties by certain directors of Savara Inc.
Investors who are current long term investors in Savara Inc. (NASDAQ: SVRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SVRA stocks…
Lawsuit filed for Investors who lost money with shares of Inspire Medical System …
An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP) have certain options and for certain investors are short and strict deadlines running. Deadline: January 5, 2026. NYSE: INSP investors should contact the Shareholders…
More Releases for Zenas
RheeGen Welcomes Renowned Molecular Biologist Dr. Zenas George to Advisory Team
RheeGen announces the appointment of Dr. Zenas George, Ph.D., as Science Advisor to support its regenerative biology and bioactive systems research.
RheeGen Registered Welcomes Renowned Molecular Biologist Dr. Zenas George to Advisory Team
RheeGen Registered announces the appointment of Dr. Zenas George, Ph.D., as Science Advisor to support its regenerative biology and bioactive systems research.
RheeGen, a biotechnology company, is proud to welcome Dr. Zenas George, Ph.D., as Science Advisor, bringing exceptional expertise…
Multiple Sclerosis Market Forecast 2034: Competitive Landscape, FDA Approvals, T …
Key multiple sclerosis companies such as Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Repertoire Immune Medicines, Nervgen, Nucleome Therapeutics, Medsenic, TeraImmun, Autobahn Therapeutics, Guangzhou Lupeng Pharmaceutical, GlaxoSmithKline, ImCyse, Novartis, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, etc
DelveInsight, a premier healthcare market research and consulting firm, proudly highlights a landmark advancement in the fight against Multiple…
Warm Autoimmune Hemolytic Anemia Market Expands Amid Increased Rare Disease Awar …
The global warm autoimmune hemolytic anemia (wAIHA) market reached US$ 617.90 Million in 2023, with a rise of US$ 711.98 Million in 2024 and is expected to reach US$ 2,789.29 Million by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033
Warm Autoimmune Hemolytic Anemia Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical…
Advances in IgG4-Related Disease Market Research & Immunotherapy By 2031 | Most …
The Global IgG4-Related Disease Market reached at a CAGR during the forecast period 2024-2031.
IgG4-Related Disease Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients…
Lawsuit filed for Investors who lost money with shares of Zenas BioPharma, Inc. …
An investor, who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO), filed a lawsuit over alleged violations of Federal Securities Laws by Zenas BioPharma, Inc. in connection with certain allegedly false and misleading statements made in connection with Zenas BioPharma's September 2024 initial public offering (the "IPO").
Investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) have certain options and for certain investors are short and strict deadlines running. Deadline:…
IgG4-related Disease Market to Show Remarkable Growth Trends from 2024 to 2034, …
DelveInsight's "IgG4-related Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the IgG4-related Disease, historical and forecasted epidemiology as well as the IgG4-related Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the IgG4-related Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgG4-related Disease Market Forecast
https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
